|
| Press Releases |
|
 |
|
| Tuesday, October 22, 2024 |
|
|
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has published the complete two-year subpopulation data from Chinese patients in the Phase 3 NefIgArd clinical trial of NEFECON under the title "Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results". more info >> |
|
| Monday, October 21, 2024 |
|
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1". There are no restrictions on initial proteinuria levels in the approved indication. more info >> |
|
| Friday, October 18, 2024 |
|
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery |
| Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
NEFECON Included in 2024 KDIGO Clinical Practice Guidelines |
| Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). more info >> |
|
| Thursday, August 22, 2024 |
|
|
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The Quantum Revolution. How Quantum Computing Will Transform the Global Economy in the Next Decade 
Jan 8, 2025 08:30 HKT/SGT
|
|
|
Stableton Partners with Alta to Expand Access to Global High-Growth Pre-IPO Investments
Jan 8, 2025 00:02 HKT/SGT
|
|
|
Asian Financial Forum held next week as the region's first major international financial assembly of 2025
Jan 7, 2025 22:33 HKT/SGT
|
|
|
CleverTap Predicts Key Trends for Customer Engagement in 2025
Jan 7, 2025 22:30 HKT/SGT
|
|
|
Graid Technology Unveils SupremeRAID(TM) AE: The AI Edition Designed for GPU-Driven AI Workloads
Jan 7, 2025 22:00 HKT/SGT
|
|
|
Mitsubishi Motors to Display Custom Versions of the Triton at Tokyo Auto Salon 2025
Jan 7, 2025 15:41 JST
|
|
|
'Toyota Woven City,' a Test Course for Mobility, Completes Phase 1 Construction and Prepares for Launch
Jan 7, 2025 15:25 JST
|
|
|
$INDX Token Pre-Sale Kicks Off as CryptoIndex.com Paves the Way for Decentralized Indexing
Jan 7, 2025 12:00 HKT/SGT
|
|
|
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Jan 7, 2025 9:14 JST
|
|
|
Spectral Achieves Major Patent Milestone Related to Quantum Computing
Jan 6, 2025 22:37 HKT/SGT
|
|
|
2025 Toys & Games Fair, Baby Products Fair, Stationery & School Supplies Fair open today
Jan 6, 2025 18:36 HKT/SGT
|
|
|
Toyota to Share Progress on Woven City at CES 2025
Jan 6, 2025 15:49 JST
|
|
|
Mazda to build Module Pack Plant for Cylindrical Lithium-ion Batteries for Automotive Use in Iwakuni City, Yamaguchi Prefecture
Jan 6, 2025 15:36 JST
|
|
|
AI Connect to Launch Revolutionary AI Agent, Redefining Financial and Technological Innovation
Jan 6, 2025 14:00 HKT/SGT
|
|
|
Celebrate Chinese New Year 2025 with Spritzer: Embrace Heartfelt & Refreshing Moments
Jan 6, 2025 12:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
